mRNA Therapeutics

Global mRNA Therapeutics Market to Reach US$34.5 Billion by 2030

The global market for mRNA Therapeutics estimated at US$13.3 Billion in the year 2024, is expected to reach US$34.5 Billion by 2030, growing at a CAGR of 17.1% over the analysis period 2024-2030. Prophylactic Products, one of the segments analyzed in the report, is expected to record a 18.3% CAGR and reach US$25.6 Billion by the end of the analysis period. Growth in the Therapeutic Products segment is estimated at 14.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 22.8% CAGR

The mRNA Therapeutics market in the U.S. is estimated at US$3.6 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.7 Billion by the year 2030 trailing a CAGR of 22.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.6% and 15.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.7% CAGR.

Global mRNA Therapeutics Market – Key Trends & Drivers Summarized

How Are mRNA Therapeutics Revolutionizing Drug Development and Disease Treatment?

The rise of mRNA therapeutics has fundamentally changed the landscape of drug development, offering a powerful platform for treating a wide range of diseases, from infectious diseases and cancer to genetic disorders and rare conditions. Unlike traditional biologics, which require complex production processes and cell culture systems, mRNA-based therapies leverage synthetic messenger RNA to instruct cells to produce therapeutic proteins directly within the body. This approach significantly accelerates drug development timelines and enhances precision in targeting disease pathways. The groundbreaking success of mRNA COVID-19 vaccines demonstrated the speed and flexibility of this technology, leading to a surge in research efforts aimed at expanding mRNA applications beyond vaccines. The ability to encode virtually any protein into an mRNA sequence has positioned this technology as a promising tool for personalized medicine, where treatments can be tailored to an individual’s genetic profile. Additionally, advancements in lipid nanoparticle (LNP) delivery systems have improved the stability and targeted delivery of mRNA therapeutics, addressing previous challenges related to degradation and immunogenicity. As pharmaceutical companies and research institutions continue to invest in mRNA-based solutions, the potential for treating conditions such as autoimmune diseases, cardiovascular disorders, and neurodegenerative conditions is rapidly expanding, making mRNA therapeutics one of the most dynamic areas in modern biotechnology.

What Technological Advancements Are Enhancing the Efficacy and Delivery of mRNA Drugs?

The rapid evolution of mRNA therapeutics is largely driven by advancements in formulation, delivery technologies, and sequence optimization. One of the most significant breakthroughs has been the development of chemically modified nucleotides, such as N1-methylpseudouridine, which enhance mRNA stability and reduce unwanted immune responses. Improved in vitro transcription (IVT) processes have increased mRNA yield and purity, reducing the presence of double-stranded RNA contaminants that can trigger inflammatory responses. The refinement of lipid nanoparticle (LNP) carriers has also played a crucial role in improving mRNA delivery, ensuring that the therapeutic payload reaches target tissues with high efficiency while minimizing off-target effects. Researchers are now exploring next-generation delivery systems, including polymer-based nanoparticles, exosome-derived vesicles, and peptide-based formulations, to further enhance tissue specificity and prolonged therapeutic effects. Additionally, the emergence of self-amplifying mRNA (saRNA) has opened new possibilities for lower-dose, longer-lasting treatments by enabling the production of therapeutic proteins at reduced mRNA concentrations. As artificial intelligence (AI) and machine learning are integrated into drug discovery, predictive modeling is being used to optimize mRNA sequences and delivery strategies, accelerating the development of novel mRNA-based therapies. These technological advancements are expected to expand the scope of mRNA therapeutics, unlocking new treatment paradigms across multiple disease areas.

How Are Regulatory and Manufacturing Challenges Impacting the mRNA Therapeutics Market?

Despite the immense potential of mRNA therapeutics, the industry faces regulatory and manufacturing challenges that must be addressed to enable widespread adoption. The highly specialized nature of mRNA production requires stringent quality control measures, particularly in raw material sourcing, in vitro transcription, and purification processes. Regulatory agencies such as the FDA and EMA have introduced new guidelines for mRNA therapeutics, focusing on product stability, immunogenicity, and manufacturing scalability. The need for Good Manufacturing Practice (GMP)-compliant production facilities has increased demand for contract development and manufacturing organizations (CDMOs) that specialize in mRNA drug production. However, the global supply chain for key components such as nucleotides, capping reagents, and lipid carriers remains vulnerable to disruptions, posing risks to large-scale manufacturing. Additionally, regulatory frameworks are still evolving for personalized mRNA therapies, such as cancer vaccines, which require customized formulations for individual patients. Another key challenge is the cost of production, as mRNA-based drugs often require cold-chain storage and sophisticated logistics for global distribution. Addressing these challenges will require continued collaboration between biotech companies, regulatory agencies, and manufacturing partners to ensure that mRNA therapeutics can be developed and distributed efficiently and safely on a global scale.

What Are the Key Growth Drivers Propelling the mRNA Therapeutics Market?

The growth in the mRNA therapeutics market is driven by several factors, including increasing investments in biotechnology research, expanding applications beyond vaccines, and technological advancements in mRNA delivery systems. The success of mRNA-based COVID-19 vaccines has significantly boosted funding for mRNA research, leading to an influx of clinical trials investigating mRNA therapies for cancer, metabolic diseases, and infectious diseases such as influenza, HIV, and Zika virus. The rise of personalized medicine has also accelerated interest in mRNA-based cancer vaccines, where patients receive customized treatments targeting specific tumor antigens. Additionally, the growing adoption of AI-driven drug discovery is streamlining mRNA sequence design, optimizing formulations, and reducing development timelines. The increasing demand for decentralized vaccine production and regional manufacturing hubs has spurred investments in mRNA production facilities, further supporting market expansion. The continued refinement of lipid nanoparticles and alternative delivery systems has enhanced the efficacy and safety of mRNA drugs, driving broader clinical adoption. Furthermore, government initiatives focused on pandemic preparedness and biopharmaceutical innovation are providing funding and regulatory support for mRNA therapeutics. As new indications emerge and manufacturing capabilities improve, the mRNA therapeutics market is poised for sustained growth, revolutionizing the treatment landscape for numerous diseases and positioning mRNA technology as a cornerstone of next-generation medicine.

SCOPE OF STUDY:

The report analyzes the mRNA Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Prophylactic Products, Therapeutic Products); Application (Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application, Other Applications); End-Use (Hospitals & Clinics End-Use, Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Abogen Biosciences
• Alnylam Pharmaceuticals
• Anima Biotech
• Arcturus Therapeutics Holdings Inc.
• BioNTech SE
• Comanche Biopharma
• CureVac N.V.
• eTheRNA Immunotherapies NV
• Ethris GmbH
• EXACIS Biotherapeutics
• Gritstone bio, Inc.
• HC Bioscience
• Inflammatix, Inc.
• Ionis Pharmaceuticals
• Moderna, Inc.
• Nutcracker Therapeutics
• Orna Therapeutics
• ReCode Therapeutics
• Strand Therapeutics
• Translate Bio (acquired by Sanofi)

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.